Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past. This golden age is also presenting tremendous opportunities for investors.
Biotech stocks offer the potential for substantial long-term returns. The best biotech stocks to buy right now boast strong pipelines, and some already have winning drugs on the market. Our pick for the day ticks all of these boxes.
Vertex Pharmaceuticals (VRTX) is the undisputed leader in cystic fibrosis therapies. The company’s portfolio of approved CF drugs will deliver at least an estimated $8.4 billion this year, made possible by intense market penetration and decades-long devotion to research and development in the space.
So far, the company has remained enormously profitable and has continued expanding revenue within the CF market. Suppose management’s plans for expanded approvals for younger cohorts continue to come to fruition over the next few years. In that case, Vertex will eventually treat as many as 90% of all people with CF.
The company is moving its pipeline beyond CF with a handful of mid-stage clinical programs for pain relief, kidney disease, and genetic hematologic disorders like sickle cell disease. In other words, even if it eventually corners the entire CF therapies market, there will still be other growth opportunities.
You might also like:
- A.I. Gamechanger Says “$2.50 Stock Set to Breakout Overnight”
- Elon’s New A.I. Device is About to Shock the World
- Prepare Now Before This Looming $2 Trillion D.C. Shock
- Write this ticker symbol down…
- “A.I. is a Tidal Wave” – Here’s What to Buy
- #1 AI Stock for 2024 and Beyond
- Bank plague 2024
- Gates, Bezos, and Buffett invest in AI Keystone
- Congress Just Fast-tracked New A.I. Energy Breakthrough
- Elon Musk: THIS will be bigger than Tesla